Latest News
-
Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy
September 19, 205
-
Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations
September 15, 2025
-
The ISSVA (International Society for the Study of Vascular Anomalies) released updates in 2025 refining classifications — notably clarifying vascular tumors vs malformations — which helps guide diagnostic workflows, referrals, treatment decisions
May 1, 2025
-
The 2025 VAC conference in Berlin) bring together researchers, clinicians, and patient-organizations to exchange and share new therapies, data, and patient perspectives. List Item
February 11-14, 2025
-
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
February 10, 2025
-
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
January 10, 2025